Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC07-523LS, CAP256V2LS, and Vesatolimod in HIV-1 Clade C-Infected Women
NCT05281510Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of vesatolimod, VRC07-523LS and CAP256V2LS in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Treatment-emergent Adverse Events at 61.1 weeks and Percentage of Participants Experiencing Treatment-emergent Graded Laboratory Abnormalities at 61.1 weeks. Started Jun 2022; status: completed.
02
Drugs
vesatolimodVRC07-523LSCAP256V2LS
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05281510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281510.